New Capital Management’s Pacira BioSciences PCRX Stock Holding History

New Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-200	Closed	-$9K	–	129
2019 Q4	$9K	Hold	200	–	–	0.01%	109
2019 Q3	$8K	Hold	200	–	–	0.01%	107
2019 Q2	$9K	Hold	200	–	–	0.02%	106
2019 Q1	$8K	Hold	200	–	–	0.02%	108
2018 Q4	$9K	Hold	200	–	–	0.02%	106
2018 Q3	$10K	Hold	200	–	–	0.02%	120
2018 Q2	$6K	Hold	200	–	–	0.01%	128
2018 Q1	$6K	Hold	200	–	–	0.02%	136
2017 Q4	$9K	Hold	200	–	–	0.01%	136
2017 Q3	$8K	Hold	200	–	–	0.01%	140
2017 Q2	$9K	Hold	200	–	–	0.02%	135
2017 Q1	$9K	Hold	200	–	–	0.02%	135
2016 Q4	$6K	Buy	+200	New	+$6.67K	0.01%	139

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

New Capital Management's PCRX Position: Q1 2020 in Review

New Capital Management sold out of Pacira BioSciences (PCRX) in Q1 2020, closing a stake of 200 shares — an estimated $9K sold.

New Capital Management first reported a position in PCRX in Q4 2016 and held it in 13 quarters. The position peaked at $10K in Q3 2018. 226 funds tracked by Wall St. Rank hold PCRX as of Q1 2020.

New Capital Management reported no remaining Pacira BioSciences position as of Q1 2020 after selling out during the quarter.
New Capital Management sold 200 Pacira BioSciences shares in Q1 2020, an estimated $9K.
New Capital Management first reported a position in Pacira BioSciences in Q4 2016 and held it in 13 quarters.
New Capital Management's Pacira BioSciences position peaked at $10K in Q3 2018.
226 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2020.

Based on New Capital Management's 13F filing for Q1 2020, filed 17 Apr 2020.